RE:New England Journal Of Medicine: InflammationAddressing inflammation, LDL and Lipoprotein-a beyond current 10 year disease management strategies are recognized in the article. This could be the sweet spot for neutraceutical options.
For cardiovascular disease:
Avenanthramide for inflammation,
beta glucan for LDL,
CoQ10 for Lipoprotein-a.
Perplexity Ai:
Coenzyme Q10 (CoQ10) has been shown to have a significant effect on lowering plasma lipoprotein(a) [Lp(a)] levels, particularly in individuals with elevated baseline levels. A systematic review and meta-analysis of randomized controlled trials indicated that CoQ10 supplementation results in a modest but statistically significant reduction in Lp(a) concentrations, with an average decrease of approximately 3.54 mg/dL. This effect was more pronounced in patients with Lp(a) levels of 30 mg/dL or higher.In clinical studies, CoQ10 supplementation has demonstrated consistent results across various doses, suggesting that it can effectively reduce Lp(a) without adversely affecting other lipid parameters such as total cholesterol or triglycerides. Additionally, some studies reported reductions in Lp(a) levels of up to 31% after just 28 days of CoQ10 treatment at a dosage of 60 mg twice daily.Overall, CoQ10 appears to be a promising nutraceutical for managing elevated Lp(a) levels, which are associated with increased cardiovascular risk. However, further research is necessary to fully understand its long-term efficacy and mechanisms of action in diverse populations.